Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARV-6723 first-in-human phase 1/2 study in advanced solid tumors
2026-525614-57-00Phase 2Authorised
- Sponsor
- Arvinas
- Start
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of ARV-6723 and pembrolizumab in Non-hematologic malignancy and cancer (2 arms), sponsored by Arvinas. Primary endpoints: First cycle dose-limiting toxicities, Adverse events and 2 more. Planned start Oct 2026; status: authorised.
02
Drugs
ARV-6723pembrolizumab
03
Conditions
Non-hematologic malignancycancer
Beyond the preview
Go deeper on 2026-525614-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525614-57-00.